Intellectus Partners’s BriaCell Therapeutics Corp Warrant BCTXW Stock Holding History

Intellectus Partners’s Portfolio BCTXW Stock Details BCTXW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-10,000	Closed	-$18K	–	278
2021 Q2	$18K	Buy	+10,000	New	+$12.5K	﹤0.01%	269

Other funds holding BCTXW

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

K.J. Harrison & Partners Toronto, Ontario, Canada $608M AUM 45.31% 1-Year Est. Return

Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return

Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return

Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Intellectus Partners's BCTXW Position: Q3 2021 in Review

Intellectus Partners sold out of BriaCell Therapeutics Corp Warrant (BCTXW) in Q3 2021, closing a stake of 10,000 shares — an estimated $18K sold.

Intellectus Partners first reported a position in BCTXW in Q2 2021 and held it in 1 quarter. The position peaked at $18K in Q2 2021. 8 funds tracked by Wall St. Rank hold BCTXW as of Q3 2021.

Intellectus Partners reported no remaining BriaCell Therapeutics Corp Warrant position as of Q3 2021 after selling out during the quarter.
Intellectus Partners sold 10,000 BriaCell Therapeutics Corp Warrant shares in Q3 2021, an estimated $18K.
Intellectus Partners first reported a position in BriaCell Therapeutics Corp Warrant in Q2 2021 and held it in 1 quarter.
Intellectus Partners's BriaCell Therapeutics Corp Warrant position peaked at $18K in Q2 2021.
8 funds tracked by Wall St. Rank held BriaCell Therapeutics Corp Warrant as of Q3 2021.

Based on Intellectus Partners's 13F filing for Q3 2021, filed 16 Nov 2021.